Arbutus Announces Year-End 2016 Financial Results
Arbutus Biopharma Corporation (ABUS)
Last arbutus biopharma corporation earnings: 11/6 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.arbutusbio.com/node/5806
Company Research
Source: GlobeNewswire
3 HBV Product Candidates in the Clinic in 1Q17Cash Runway into Late 2018Company to Host a Corporate Update Conference Call Today at 2:00 PM ET VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced its 2016 financial results and provided a corporate update. “Arbutus made significant progress in 2016, including demonstrating significant HBsAg reduction in the Phase II trial of ARB-1467,” said Dr. Mark J. Murray, Arbutus’ President and CEO. “We are excited to build on this progress in 2017 with three HBV product candidates in clinical development by the end of 1Q17, continued productivity from our research effort, and additional studies to explore the full potential of ARB-1467 and combining RNAi agents with standard of care in HBV patients.” Recent Highlights and Developments ARB-1467 Phase II Cohort 3 in HBeAg+ patie
Show less
Read more
Impact Snapshot
Event Time:
ABUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABUS alerts
High impacting Arbutus Biopharma Corporation news events
Weekly update
A roundup of the hottest topics
ABUS
News
- Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments [Yahoo! Finance]Yahoo! Finance
- Arbutus to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Arbutus to Participate in Two Upcoming Investor ConferencesGlobeNewswire
- Arbutus Biopharma Corporation (NASDAQ:ABUS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report [Yahoo! Finance]Yahoo! Finance
- Analysts Just Made A Major Revision To Their Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenue Forecasts [Yahoo! Finance]Yahoo! Finance
ABUS
Earnings
- 11/7/23 - In-Line
ABUS
Sec Filings
- 3/5/24 - Form 10-K
- 2/29/24 - Form 8-K
- 2/14/24 - Form SC
- ABUS's page on the SEC website